Vanguard Group Inc. Purchases 607,447 Shares of Privia Health Group, Inc. $PRVA

Vanguard Group Inc. raised its holdings in shares of Privia Health Group, Inc. (NASDAQ:PRVA) by 5.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,098,933 shares of the company’s stock after acquiring an additional 607,447 shares during the quarter. Vanguard Group Inc. owned approximately 9.86% of Privia Health Group worth $301,263,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. CWM LLC lifted its holdings in Privia Health Group by 89.4% in the 2nd quarter. CWM LLC now owns 3,416 shares of the company’s stock worth $79,000 after purchasing an additional 1,612 shares in the last quarter. Canada Pension Plan Investment Board boosted its position in shares of Privia Health Group by 48.0% during the second quarter. Canada Pension Plan Investment Board now owns 3,700 shares of the company’s stock worth $85,000 after acquiring an additional 1,200 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Privia Health Group during the second quarter valued at $113,000. Covestor Ltd increased its holdings in Privia Health Group by 39.8% in the 3rd quarter. Covestor Ltd now owns 5,824 shares of the company’s stock valued at $145,000 after acquiring an additional 1,657 shares during the last quarter. Finally, Acadian Asset Management LLC bought a new stake in Privia Health Group in the 1st quarter valued at $154,000. 94.48% of the stock is currently owned by hedge funds and other institutional investors.

Privia Health Group Trading Down 4.7%

PRVA stock opened at $23.75 on Friday. The stock has a market cap of $2.92 billion, a PE ratio of 139.71, a P/E/G ratio of 1.72 and a beta of 0.83. Privia Health Group, Inc. has a 12 month low of $18.77 and a 12 month high of $26.51. The company has a 50-day moving average price of $23.07 and a 200 day moving average price of $23.46.

Privia Health Group (NASDAQ:PRVA) last announced its earnings results on Thursday, February 26th. The company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.21. Privia Health Group had a return on equity of 3.12% and a net margin of 1.08%.The business had revenue of $541.17 million during the quarter, compared to analyst estimates of $516.61 million. During the same quarter in the previous year, the business earned $0.21 earnings per share. The company’s revenue for the quarter was up 17.4% compared to the same quarter last year. Sell-side analysts forecast that Privia Health Group, Inc. will post 0.14 EPS for the current year.

Key Stories Impacting Privia Health Group

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Q4 and full‑year 2025 results beat expectations and management delivered bullish 2026 guidance — revenue, EPS and adjusted EBITDA came in above guidance with adjusted EBITDA up strongly Y/Y and management guiding ~20% adjusted EBITDA growth (midpoint) and expansion to 24 states. This is the main fundamental driver supporting upside. GlobeNewswire
• Positive Sentiment: Analyst optimism: Canaccord recently raised its PRVA price target (to $35) and the mean analyst target implies material upside; several outlets highlight a consensus uplift in price targets — supportive for further analyst‑driven buying. Canaccord / Benzinga coverage
• Positive Sentiment: Company guidance emphasizes converting ~80% of adjusted EBITDA to free cash flow and ending 2026 with ~ $600M cash, plus no debt — balance‑sheet strength that can underwrite organic growth or M&A. MSN / coverage of guidance
• Neutral Sentiment: Supporting disclosure and materials: transcript and slide deck from the earnings call are available for deeper read — useful for modeling cadence of revenue/EBITDA conversions and provider growth assumptions. Earnings transcript (Yahoo)
• Negative Sentiment: Offset risks: large non‑cash stock‑based compensation ($71.1M in 2025), management’s note that forward non‑GAAP measures aren’t reconciled to GAAP (adding forecasting uncertainty), and disclosure of insider sales in recent months — items that can temper investor enthusiasm. QuiverQuant / release summary
• Negative Sentiment: Valuation and market action: PRVA trades at a high trailing P/E and the stock is seeing elevated volume today — likely profit‑taking or rotation despite the beat. That dynamic, plus at least one lower analyst target in the mix historically, helps explain short‑term downward pressure.

Analysts Set New Price Targets

Several brokerages have recently issued reports on PRVA. Barclays lifted their target price on Privia Health Group from $22.00 to $23.00 and gave the stock an “equal weight” rating in a report on Monday, November 10th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Privia Health Group in a report on Monday, December 29th. Jefferies Financial Group reissued a “buy” rating and issued a $32.00 target price on shares of Privia Health Group in a report on Thursday. Piper Sandler reaffirmed an “overweight” rating and set a $36.00 price target on shares of Privia Health Group in a research note on Thursday. Finally, Canaccord Genuity Group lifted their price objective on shares of Privia Health Group from $34.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday. Thirteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $30.79.

Insider Transactions at Privia Health Group

In related news, Director Matthew Shawn Morris sold 13,647 shares of the stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $25.01, for a total value of $341,311.47. Following the transaction, the director owned 68,188 shares of the company’s stock, valued at $1,705,381.88. This represents a 16.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO David Mountcastle sold 23,887 shares of Privia Health Group stock in a transaction on Friday, December 12th. The shares were sold at an average price of $25.03, for a total value of $597,891.61. Following the sale, the chief financial officer directly owned 172,909 shares of the company’s stock, valued at approximately $4,327,912.27. This trade represents a 12.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 10.70% of the company’s stock.

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.